Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis

Overview of attention for article published in Frontiers in oncology, July 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#12 of 22,436)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 52 news outlets
policy: 1 policy source

twitter: 7 X users

Citations

dimensions_citation: 34 Dimensions

Readers on

mendeley: 52 Mendeley

Summary News Policy documents X Dimensions citations

So far, Dimensions has found 34 publications that cite this research output.

34

The most recent citing publications are shown below. View all 34 publications that cite this research output on Dimensions.

GD2 targeting CAR T cells for neuroblastoma

Article (December 2024)

Current cell therapies for systemic lupus erythematosus

Article in Stem Cells Translational Medicine (June 2024)

Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin’s Lymphoma

Article in Pathogens and Immunity (March 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.